The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
Discover how this diabetes drug is revolutionizing heart health. Learn about its surprising benefits in reducing cardiovascular risks and mortality.
The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as ...
The FDA has determined that the nationwide shortage of semaglutide injection, used for both diabetes and weight loss, is resolved after more than two years of limited availability due to high demand.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results